Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity

被引:62
作者
Lilitkarntakul, Pajaree [1 ]
Dhaun, Neeraj [1 ,2 ]
Melville, Vanessa [1 ]
Blackwell, Scott [2 ]
Talwar, Dinesh K. [3 ]
Liebman, Barbara [1 ]
Asai, Takae [1 ]
Pollock, Jennifer [4 ]
Goddard, Jane [2 ]
Webb, David J. [1 ]
机构
[1] Univ Edinburgh, Queens Med Res Inst, Ctr Res Excellence CoRE, Clin Pharmacol Unit, Edinburgh EH16 4TJ, Midlothian, Scotland
[2] Royal Infirm Edinburgh NHS Trust, Dept Renal Med, Edinburgh, Midlothian, Scotland
[3] Glasgow Royal Infirm, Dept Clin Biochem & Metab Med, Glasgow, Lanark, Scotland
[4] Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA
关键词
Chronic kidney disease; Endothelin; Nitric oxide; Asymmetric dimethylarginine; Inflammation; Oxidative stress; ASYMMETRIC DIMETHYLARGININE; CARDIOVASCULAR-DISEASE; AORTIC STIFFNESS; DEPENDENT VASODILATATION; RENAL-FUNCTION; RISK; HEMODIALYSIS; EPIDEMIOLOGY; INFLAMMATION; PERFORMANCE;
D O I
10.1016/j.atherosclerosis.2011.01.045
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Patients with chronic kidney disease (CKD) have increased risk of cardiovascular disease to which co-morbidity and associated conventional risk factors contribute. We hypothesised that arterial stiffness (AS) and endothelial dysfunction (ED), as surrogates of cardiovascular risk, would worsen as renal function declined even in patients without co-morbidity and that this would relate to emerging cardiovascular risk factors. Methods: Carotid-femoral pulse wave velocity (PWV), as a measure of AS, and flow-mediated dilatation (FMD) of the brachial artery, as a measure of ED, were assessed in CKD patients without established cardiovascular disease or diabetes mellitus. Results: PWV increased linearly as renal function declined (r(2) = 0.08, p < 0.01) whereas FMD was reduced only in patients with advanced kidney disease. In multivariable analysis, blood pressure was the major determinant of PWV and FMD. High-sensitivity C-reactive protein and asymmetric dimethylarginine, and isoprostanes and endothelin-1, were independent predictors of PWV and FMD, respectively. However, renal function did not independently predict either AS or ED. Conclusions: These findings suggest that declining renal function, in the absence of significant comorbidity, is associated with progressive arterial stiffness, but only patients close to dialysis exhibit endothelial dysfunction. Whilst blood pressure remains the major determinant of PWV and FMD, inflammation, oxidative stress and endothelin-nitric oxide balance contribute to cardiovascular risk, in this non-comorbid cohort. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:217 / 225
页数:9
相关论文
共 50 条
[1]   Impaired endothelium-dependent vasodilatation in renal failure in humans [J].
Annuk, M ;
Lind, L ;
Linde, T ;
Fellström, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (02) :302-306
[2]   Impact of aortic stiffness on survival in end-stage renal disease [J].
Blacher, J ;
Guerin, AP ;
Pannier, B ;
Marchais, SJ ;
Safar, ME ;
London, GM .
CIRCULATION, 1999, 99 (18) :2434-2439
[3]   Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma [J].
Blackwell, S. ;
O'Reilly, D. St. J. ;
Talwar, D. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (05) :364-371
[4]   The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor [J].
Böger, RH .
CARDIOVASCULAR RESEARCH, 2003, 59 (04) :824-833
[5]   The hematocrit-corrected erythrocyte sedimentation rate can be useful in diagnosing inflammation in hemodialysis patients [J].
Borawski, J ;
Mysliwiec, M .
NEPHRON, 2001, 89 (04) :381-383
[6]   Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery - A report of the International Brachial Artery Reactivity Task Force [J].
Corretti, MC ;
Anderson, TJ ;
Benjamin, EJ ;
Celermajer, D ;
Charbonneau, F ;
Creager, MA ;
Deanfield, J ;
Drexler, H ;
Gerhard-Herman, M ;
Herrington, D ;
Vallance, P ;
Vita, J ;
Vogel, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) :257-265
[7]   Endothelin and cardiovascular remodelling in end-stage renal disease [J].
Demuth, K ;
Blacher, J ;
Guerin, AP ;
Benoit, MO ;
Moatti, N ;
Safar, ME ;
London, GM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (02) :375-383
[8]   The endothelin system and its antagonism in chronic kidney disease [J].
Dhaun, Neeraj ;
Goddard, Jane ;
Webb, David J. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (04) :943-955
[9]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[10]   Endothelial dysfunction [J].
Endemann, DH ;
Schiffrin, EL .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :1983-1992